European Penny Stocks To Watch In July 2026

The European markets have shown resilience with the pan-European STOXX Europe 600 Index rising by 1.96% in recent days, buoyed by lower oil prices and easing inflation concerns. This positive sentiment provides a backdrop for investors to explore various opportunities, including those found in penny stocks. Although the term 'penny stock' may seem outdated, these smaller or newer companies can still offer significant growth potential when backed by strong financials. We'll highlight several penny stocks that stand out for their financial strength and potential to deliver long-term success in today's market conditions.

We'll examine a selection from our screener results.

Oryzon Genomics (BME:ORY)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Oryzon Genomics S.A. is a clinical stage biopharmaceutical company focused on developing epigenetics-based therapeutics for cancer and CNS, oncology, and hematology disorders, with a market cap of €240.63 million.

Operations: Oryzon Genomics S.A. has not reported any specific revenue segments.

Market Cap: €240.63M

Oryzon Genomics is a pre-revenue company with a focus on developing epigenetics-based therapeutics, currently showcasing promising clinical data for its LSD1 inhibitor, iadademstat. Recent trials in acute myeloid leukemia (AML) have demonstrated high response rates and favorable safety profiles. The company completed a €12 million equity offering to support its pipeline development. Despite being unprofitable, Oryzon's financial position appears stable with short-term assets exceeding liabilities and more cash than debt. However, the board's relative inexperience might be seen as a risk factor by some investors interested in penny stocks within the biotech sector.

• Take a closer look at Oryzon Genomics' potential here in our financial health report.
• Explore Oryzon Genomics' analyst forecasts in our growth report.

Aquila Part Prod Com (BVB:AQ)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Aquila Part Prod Com S.A. operates in distribution and logistics services across several countries including Romania, Moldova, and Poland, with a market capitalization of RON2.18 billion.

Operations: The company's revenue is derived from three main segments: Distribution (RON3.39 billion), Logistics (RON113.58 million), and Transport (RON62.13 million).

Market Cap: RON2.18B

Aquila Part Prod Com S.A. operates in distribution and logistics with a market cap of RON2.18 billion, demonstrating stable financial management with satisfactory net debt to equity ratio (24.6%) and well-covered interest payments (4.9x EBIT). Despite a decline in earnings growth (-61.8% last year), the company maintains high-quality earnings and has reduced its debt significantly over five years, from 274.7% to 29.8%. Recent Q1 results showed increased sales (RON835.29 million) but lower net income (RON3.29 million). The company's seasoned management team provides stability amidst challenges in profit margin improvement and low return on equity (6.4%).

• Click here to discover the nuances of Aquila Part Prod Com with our detailed analytical financial health report.
• Understand Aquila Part Prod Com's earnings outlook by examining our growth report.

Enzymatica (OM:ENZY)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Enzymatica AB (publ) is a life science company that develops and sells medical devices for infectious diseases, with a market cap of SEK604.41 million.

Operations: The company generates revenue of SEK53.06 million from its medical devices segment.

Market Cap: SEK604.41M

Enzymatica AB, with a market cap of SEK604.41 million, is navigating challenges typical of penny stocks. The company remains unprofitable and has seen earnings decline by 5.6% annually over the past five years. Its cash runway is less than a year, indicating potential financial strain if revenue does not improve. Recent developments include concerns raised by PLOS ONE about the Berlin II study's exploratory analyses but do not affect ColdZyme’s regulatory status or marketing claims, supported by other studies like Davison 2025. Additionally, strategic leadership changes aim to boost ColdZyme's Nordic market presence ahead of the cold season.

• Get an in-depth perspective on Enzymatica's performance by reading our balance sheet health report here.
• Understand Enzymatica's track record by examining our performance history report.

Key Takeaways

• Take a closer look at our European Penny Stocks list of 307 companies by clicking here.
• Seeking Other Investments? These 25 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com